Xeris Biopharma shares are trading higher after the company tightened FY23 revenue guidance and raised 2023 cash, cash equivalents and short-term investment guidance.
Portfolio Pulse from Benzinga Newsdesk
Xeris Biopharma has revised its FY23 revenue guidance and increased its 2023 cash, cash equivalents and short-term investment guidance. This has led to a rise in the company's share prices.
October 16, 2023 | 4:44 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Xeris Biopharma's shares are trading higher after the company revised its FY23 revenue guidance and increased its 2023 cash, cash equivalents and short-term investment guidance.
Xeris Biopharma's decision to revise its FY23 revenue guidance and increase its 2023 cash, cash equivalents and short-term investment guidance indicates a positive financial outlook for the company. This has led to increased investor confidence, resulting in a rise in the company's share prices.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100